Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
RDY
DR. REDDY'S LABORATORIES LIMITED
NYSE
$11.91
▲ UP 0.08% (0.01)

KEY STATISTICS

Market Cap$9.91 B
52w High$15.67
52w Low$11.36
Dividend Yield1.09%
FrequencyIrregular
P/E19.52
Volume2.41M
Shares Out.832.95M

COMPANY

LEADERSHIP

Erez Israeli
CHIEF EXECUTIVE
Erez Israeli

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 11, 2001
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
27,527

UPCOMING EARNINGS

DateOct 23, 2026
DayFriday
Rev. Est.$843.48M
OCT
23
FRI

SPLIT RECORD

DATETYPERATIO
2024-11-05Forward5:1
2006-09-07Forward2:1

PRICE

$11.91 ▲ UP 0.08% (+$0.01)
OVERLAYS
$11.88$11.90$11.939:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM11.91

About Dr. Reddy's Laboratories Limited

https://www.drreddys.com ↗

Dr. Reddy's Laboratories is a global integrated pharmaceutical company specializing in generics, active ingredients, proprietary formulations, and oncology, with operations in R&D, manufacturing, and contract services.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT DR. REDDY'S LABORATORIES LIMITED IS KNOWN FOR

Generic Semaglutide
Generic Semaglutide

Dr. Reddy's plans to launch a generic GLP-1 receptor agonist in India and Canada in early 2026, capitalizing on the growing market for type 2 diabetes and obesity treatments as patents for branded versions expire.

COMPETITORS

COMPETITOR
LLY COMPARE
NVO COMPARE
PFE COMPARE
TEVA COMPARE
VTRS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
62
LISTED HERE
14
RANKED BY POSITION SIZE
EMOP
2.09% · 3.8M
VWO
0.01% · 1.9M
AVEM
0.07% · 1.8M
SPEM
0.10% · 1.5M
DFEM
0.05% · 382.9K
FWRA.SW
0.08% · 366.3K
EMEQ
0.26% · 137.0K
JEMA
0.08% · 125.5K
EDOG
2.18% · 54.6K
FNI
3.45% · 51.2K
APIE
0.05% · 45.3K
NSI
0.54% · 19.3K
SPWO
0.08% · 15.4K
BFLX
-0.06% · -111.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
11.59%
HOLDERS
377
TOP 12 OF 377 · RANKED BY POSITION SIZE
Robeco Institutional Asset Management B.V.
18.0M sh · $261.13M
Blackrock, Inc.
11.6M sh · $160.48M
Morgan Stanley
10.9M sh · $158.47M
Royal Bank Of Canada
10.2M sh · $142.07M
Renaissance Technologies LLC
8.8M sh · $122.78M
Aikya Investment Management Ltd
8.5M sh · $123.08M
Jpmorgan Chase & Co
6.0M sh · $84.27M
Dimensional Fund Advisors LP
5.4M sh · $75.22M
Vanguard Group Inc
5.1M sh · $71.63M
State Street Corp
4.2M sh · $58.13M
Bnp Paribas Arbitrage, Snc
4.2M sh · $58.3M
Alliancebernstein L.P.
3.7M sh · $51.67M

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity4
Return On Assets4
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score3

INSIDER TRADES

★
OFFICER: GLOBAL HEAD OF QUALITY AND PV
MUNNIRPALLAM MADHU SUNDAR SUBRAMANIAN
— · —
2026-04-01
★
OFFICER: CHIEF FINANCIAL OFFICER
MANNAM VENKATA NARASIMHAM
— · —
2025-12-18
★
OFFICER: CEO - API AND SERVICES
SAPRA DEEPAK
— · —
2025-12-18
★
DIRECTOR:
Seth Alpna
— · —
2025-12-18

SECTORS PEERS

PEERPRICE
RVMD$204.78COMPARE
VTRS$16.68COMPARE
NBIX$157.84COMPARE
SOLV$88.66COMPARE
EXEL$56.34COMPARE
RVTY$125.77COMPARE
BMRN$66.61COMPARE
EHC$122.57COMPARE